Lipid-lowering therapies in patients undergoing percutaneous coronary intervention

Abstract

Cardiovascular disease is the leading cause of death worldwide. Over past decades, multiple clinical trials have provided substantial evidence supporting the advantages of managing plasma lipids in individuals with coronary artery disease (CAD). A primary focus in reducing clinical atherosclerotic cardiovascular disease (ASCVD) in patients who have undergone percutaneous coronary intervention (PCI) is the regulation of blood lipids, with an emphasis on low-density lipoprotein (LDL) cholesterol. Statins represent the cornerstone of lipid-lowering therapy (LLT), with high-intensity statins consistently associated with beneficial outcomes in patients at high risk of ASCVD. Nevertheless, a notable portion of patients do not achieve their target cholesterol levels through statin monotherapy, necessitating the inclusion of complementary LLT strategies. Among these therapies are ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, which have also demonstrated clinical advantages by further reducing cholesterol levels. Existing guidelines recommend using these agents when maximally tolerated statin doses fall short of achieving target LDL levels. Additionally, recently introduced ATP-citrate lyase inhibitors, such as bempedoic acid, have gained approval as adjunctive treatments. Furthermore, icosapent ethyl, a purified derivative of eicosapentaenoic acid, targets hypertriglyceridemia and has shown cardiovascular benefits compared to placebo. In this article, we delve into the mechanisms of blood lipids and molecular targets in connection with CAD undergoing PCI. We also explore the current landscape of available LLT options, guidelines in practice, and the subtleties of therapy.

Keywords

3-hydroxy-methylglutaryl coenzyme A inhibitors / cardiovascular disease / ezetimibe / familial hypercholesterolemia / hypertriglyceridemia / icosapent ethyl / low-density lipoprotein / non-statin lipid-lowering therapies / PCSK9 inhibitors

References

[1] WHO CVD Risk Chart Working GroupWorld Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions.Lancet Glob Health2019;7:e1332-45

[2] Roth GA,Johnson CO.Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study.J Am Coll Cardiol2020;76:2982-3021

[3] Grundy SM. Guidelines for the management of high blood cholesterol. In: Feingold KR, Anawalt B, Blackman MR, editors. Endotext South Dartmouth, MA: MDText.com, Inc.; 2000.

[4] Grundy SM. Guidelines for the management of high blood cholesterol. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305897/ [Last accessed on 3 Apr 2024]

[5] Feher MD.Lipid lowering to delay the progression of coronary artery disease.Heart2003;89:451-8 PMCID:PMC1769281

[6] Vaughan CJ,Basson CT.The evolving role of statins in the management of atherosclerosis.J Am Coll Cardiol2000;35:1-10

[7] Silverman MG,Im K.Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis.JAMA2016;316:1289-97

[8] Fulcher J,Voysey M.Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.Lancet2015;385:1397-405

[9] Grundy SM,Bailey AL.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines.J Am Coll Cardiol2019;73:e285-350

[10] Mach F,Catapano AL.Corrigendum to: 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Eur Heart J2020;41:4255

[11] Mach F,Catapano AL.2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS).Eur Heart J2020;41:111-88

[12] Qiao YN,Guo SD.Low-density lipoprotein particles in atherosclerosis.Front Physiol2022;13:931931 PMCID:PMC9468243

[13] Weitgasser R,Hemetsberger M.LDL-cholesterin und kardiovaskuläre ereignisse: je niedriger desto besser? LDL-cholesterol and cardiovascular events: the lower the better.Wien Med Wochenschr2018;168:108-20

[14] Ference BA,Penumetcha R,Brook RD.Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.J Am Coll Cardiol2015;65:1552-61 PMCID:PMC6101243

[15] Sniderman AD,Glavinovic T.Apolipoprotein B particles and cardiovascular disease: a narrative review.JAMA Cardiol2019;4:1287-95 PMCID:PMC7369156

[16] Borén J.The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity.Curr Opin Lipidol2016;27:473-83

[17] Behbodikhah J,Elyasi A.Apolipoprotein B and Cardiovascular disease: biomarker and potential therapeutic target.Metabolites2021;11:690 PMCID:PMC8540246

[18] Han SH,Sakuma I,Koh KK.Hypertriglyceridemia and cardiovascular diseases: revisited.Korean Circ J2016;46:135-44 PMCID:PMC4805556

[19] Sarwar N,Eiriksdottir G.Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.Circulation2007;115:450-8

[20] Talmud PJ,Miller GJ.Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men.Arterioscler Thromb Vasc Biol2002;22:1918-23

[21] Navar AM.The evolving story of triglycerides and coronary heart disease risk.JAMA2019;321:347-9

[22] Marston NA,Im K.Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials.Circulation2019;140:1308-17 PMCID:PMC6791781

[23] Zhang BH,Qiao YN.Triglyceride and triglyceride-rich lipoproteins in atherosclerosis.Front Mol Biosci2022;9:909151 PMCID:PMC9174947

[24] Bhatt DL,Miller M.Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.N Engl J Med2019;380:11-22

[25] Yeshurun D,Jr .Hyperlipidemia: perspectives in diagnosis and treatment.South Med J1995;88:379-91

[26] Gravina CF,Rodrigues GH.Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly.J Geriatr Cardiol2012;9:83-90 PMCID:PMC3418895

[27] Riccardi G,Calabrese I.Dietary recommendations for prevention of atherosclerosis.Cardiovasc Res2022;118:1188-204

[28] The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease.JAMA1984;251:351-64

[29] National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II).Circulation1994;89:1333-445

[30] Chou R,Dana T.Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US preventive services task force.JAMA2022;328:754-71

[31] Naci H,Ades T.Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.Circ Cardiovasc Qual Outcomes2013;6:390-9

[32] Davidson MH.Safety of aggressive lipid management.J Am Coll Cardiol2007;49:1753-62

[33] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S).Lancet1994;344:1383-9

[34] Sacks FM,Moye LA.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators.N Engl J Med1996;335:1001-9

[35] The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.N Engl J Med1998;339:1349-57

[36] Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet2002;360:7-22

[37] Sato H,Ito H.Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID Study.Circ J2008;72:17-22

[38] Athyros VG,Mercouris BR.Treatment with atorvastatin to the national cholesterol educational program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and coronary-heart-disease evaluation (GREACE) study.Curr Med Res Opin2002;18:220-8

[39] Koren MJ.Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.J Am College Cardiol2004;44:1772-9

[40] LaRosa JC,Waters DD.Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med2005;352:1425-35

[41] Taguchi I,Iwata H.High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial.Circulation2018;137:1997-2009

[42] The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT).JAMA2002;288:2998-3007

[43] Pedersen TR,Kastelein JJ.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.JAMA2005;294:2437-45

[44] Baigent C,Emberson J.Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.Lancet2010;376:1670-81 PMCID:PMC2988224

[45] Nissen SE,Schoenhagen P.Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.JAMA2004;291:1071-80

[46] Campeau L,Knatterud GL.Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial..Circulation1999;99:3241-7

[47] Taylor AJ,Flaherty PJ,Markwood TT.ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.Circulation2002;106:2055-60

[48] Smilde TJ,Awollersheim H,Kastelein JJP.Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.Lancet2001;357:577-81

[49] Schwartz GG,Ezekowitz MD.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.JAMA2001;285:1711-8

[50] Dohi T,Okazaki S.Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study.Atherosclerosis2010;210:497-502

[51] de Lemos JA,Wiviott SD.Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.JAMA2004;292:1307-16

[52] Cannon CP,McCabe CH.Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med2004;350:1495-504

[53] Pasceri V,Nusca A,Richichi G.ARMYDA InvestigatorsRandomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.Circulation2004;110:674-8

[54] Patti G,Colonna G.Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.J Am Coll Cardiol2007;49:1272-8

[55] Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (atorvastatin for reduction of myocardial damage during angioplasty) randomized trial.J Am Coll Cardiol2009;54:558-65

[56] Kim JS,Choi D.Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.JACC Cardiovasc Interv2010;3:332-9

[57] Briguori C,Focaccio A.Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.J Am Coll Cardiol2009;54:2157-63

[58] Sardella G,Donahue M.Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial.Catheter Cardiovasc Interv2013;81:E36-43

[59] Okazaki S,Miyauchi K.Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study.Circulation2004;110:1061-8

[60] Dupuis J,Cernacek P.Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial.Circulation1999;99:3227-33

[61] Cannon CP,Giugliano RP.Ezetimibe added to statin therapy after acute coronary syndromes.N Engl J Med2015;372:2387-97

[62] Ouchi Y,Arai H.Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial.Circulation2019;140:992-1003

[63] Wilson PWF,Miedema MD,Kosinski AS.Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines.Circulation2019;139:e1144-61

[64] Ah YM,Choi HD.Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: a meta-analysis of randomized controlled studies.PLoS One2022;17:e0264437 PMCID:PMC8896700

[65] Hu H,Ma J.Two novel disease-causing mutations in the LDLR of familial hypercholesterolemia.Front Genet2021;12:762587 PMCID:PMC8712701

[66] Di Taranto MD, Giacobbe C, Fortunato G. Familial hypercholesterolemia: a complex genetic disease with variable phenotypes.Eur J Med Genet2020;63:103831

[67] Ji E.Antibody-based therapeutics for atherosclerosis and cardiovascular diseases.Int J Mol Sci2021;22:5770 PMCID:PMC8199089

[68] Manniello M.Alirocumab (praluent): first in the new class of PCSK9 inhibitors.P T2016;41:28-53 PMCID:PMC4699483

[69] Kasichayanula S,Emery MG.Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor.Clin Pharmacokinet2018;57:769-79 PMCID:PMC5999140

[70] Guedeney P,Giustino G.Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis.Eur Heart J Cardiovasc Pharmacother2021;7:225-35

[71] Sabatine MS,Keech AC.Evolocumab and clinical outcomes in patients with cardiovascular disease.N Engl J Med2017;376:1713-22

[72] Schwartz GG,Szarek M.Alirocumab and cardiovascular outcomes after acute coronary syndrome.N Engl J Med2018;379:2097-107

[73] Kereiakes DJ,Cannon CP.Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study.Am Heart J2015;169:906-15.e13

[74] Robinson JG,Krempf M.Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.N Engl J Med2015;372:1489-99

[75] Moriarty PM,Cannon CP.Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial.J Clin Lipidol2015;9:758-69

[76] Cannon CP,Blom D.Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.Eur Heart J2015;36:1186-94 PMCID:PMC4430683

[77] Ray KK,Müller-Wieland D.Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial.Diabetes Obes Metab2018;20:1479-89 PMCID:PMC5969299

[78] Nicholls SJ,Anderson T.Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial.JAMA2016;316:2373-84

[79] Koskinas KC,Pedrazzini G.Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS).J Am Coll Cardiol2019;74:2452-62

[80] Wang HF,Xu XY.Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: a meta-analysis focusing on the number needed to treat.Front Cardiovasc Med2022;9:1016802 PMCID:PMC9755489

[81] Toth PP,Gandra SR.Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia.J Am Heart Assoc2017;6:e005367 PMCID:PMC5721820

[82] Wang N.A new approach to PCSK9 therapeutics.Circ Res2017;120:1063-5 PMCID:PMC5848492

[83] Kosmas CE,Skavdis A,Martinez I.Inclisiran for the treatment of cardiovascular disease: a short review on the emerging data and therapeutic potential.Ther Clin Risk Manag2020;16:1031-7 PMCID:PMC7604242

[84] Nishikido T.Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease.Cardiovasc Diabetol2023;22:20 PMCID:PMC9887852

[85] Ray KK,Kallend D.Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.N Engl J Med2020;382:1507-19

[86] Koenig W,Landmesser U.Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10, and ORION-11 phase 3 randomized controlled trials. Cardiovasc Drugs Ther 2022

[87] Brandts J.Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.Expert Opin Investig Drugs2020;29:763-70

[88] Nissen SE,Brennan D.Bempedoic acid and cardiovascular outcomes in statin-intolerant patients.N Engl J Med2023;388:1353-64

[89] Bazarbashi N.Icosapent ethyl: niche drug or for the masses?.Curr Cardiol Rep2020;22:104

[90] Budoff MJ,Kinninger A.Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.Eur Heart J2020;41:3925-32 PMCID:PMC7654934

[91] Borghi C.Clinical results and mechanism of action of icosapent ethyl.Eur Heart J Suppl2023;25:B37-40 PMCID:PMC10120946

[92] Staels B,Auwerx J,Leitersdorf E.Mechanism of action of fibrates on lipid and lipoprotein metabolism.Circulation1998;98:2088-93

[93] Jakob T,Schandelmaier S,Briel M.Fibrates for primary prevention of cardiovascular disease events.Cochrane Database Syst Rev2016;11:CD009753 PMCID:PMC6464497

[94] Alder M,Zumpf K,Stone NJ.A meta-analysis assessing additional LDL-C reduction from addition of a bile acid sequestrant to statin therapy.Am J Med2020;133:1322-7

[95] Charles MA.New molecular insights into CETP structure and function: a review.J Lipid Res2012;53:1451-8 PMCID:PMC3540851

[96] Bowman L,Chen F.Effects of anacetrapib in patients with atherosclerotic vascular disease.N Engl J Med2017;377:1217-27

[97] Chambergo-Michilot D,Kulkarni S.Mipomersen in familial hypercholesterolemia: an update on health-related quality of life and patient-reported outcomes.Vasc Health Risk Manag2022;18:73-80 PMCID:PMC8880726

[98] Alonso R,Mata P.Lomitapide: a review of its clinical use, efficacy, and tolerability.Core Evid2019;14:19-30 PMCID:PMC6615460

[99] Fogacci F,Toth PP,Corsini A.Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials.Drugs2019;79:751-66

[100] Astaneh B,Astaneh V.The effect of mipomersen in the management of patients with familial hypercholesterolemia: a systematic review and meta-analysis of clinical trials.J Cardiovasc Dev Dis2021;8:82 PMCID:PMC8304130

[101] D’Erasmo L,Noto D.Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy.Adv Ther2017;34:1200-10

[102] D’Erasmo L,Nicolucci A.Autosomal recessive hypercholesterolemia: long-term cardiovascular outcomes.J Am Coll Cardiol2018;71:279-88

[103] Cuchel M,du Toit Theron H.Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.Lancet2013;381:40-6 PMCID:PMC4587657

[104] van Lennep J, Averna M, Alonso R. Treating homozygous familial hypercholesterolemia in a real-world setting: experiences with lomitapide.J Clin Lipidol2015;9:607-17

[105] D’Erasmo L,Cefalù AB.Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study.Eur J Prev Cardiol2022;29:832-41

[106] Orringer CE,Saseen JJ.Update on the use of PCSK9 inhibitors in adults: recommendations from an expert panel of the national lipid association.J Clin Lipidol2017;11:880-90

[107] Grundy SM,Merz CN.Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines.Circulation2004;110:227-39

[108] Nußbaumer B,Kaminski-Hartenthaler A,Gartlehner G.Ezetimibe-statin combination therapy.Dtsch Arztebl Int2016;113:445-53 PMCID:PMC4946327

[109] Khan SU,Lone AN.PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.BMJ2022;377:e069116

[110] Kenneth R. Cholesterol lowering drugs. Endotext South Dartmouth, MA: MDText.com, Inc.; 2000.

[111] Park IS,Song SH.Ticagrelor-induced acute kidney injury can increase serum concentration of statin and lead to concurrence of rhabdomyolysis.Anatol J Cardiol2018;19:225-6 PMCID:PMC5864774

[112] Newman CB.Safety of statins and nonstatins for treatment of dyslipidemia.Endocrinol Metab Clin North Am2022;51:655-79

[113] Hagiwara N,Koyanagi R.Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.Eur Heart J2017;38:2264-76 PMCID:PMC5837267